Company shares surged in after-market trading on results for a drug Vertex acquired in a multibillion-dollar deal and sees as ...

The result “pulls the rug” out from under giredestrant, according to one analyst, sparking another share selloff following disappointing obesity data last week.

Ipsen found cases of secondary malignancies in a confirmatory study of Tavzerik, a medicine it got in a purchase of Epizyme ...

Prasad contributed to an uncertain regulatory climate for gene therapy makers focused on rare conditions. Shares of many ...

Organizations that transition steady, high-volume lanes to engineered reusable systems often see 30–50% reductions in ...

The therapy, mezigdomide, is part of group of medicines the pharma sees as successors to its lucrative multiple myeloma drugs ...

Prasad’s planned departure, expected at the end of April, culminates a tumultuous term in which he reworked vaccine ...

The agreement ends a messy dispute that began when the telehealth firm attempted to sell a compounded form of Novo’s Wegovy pill at a cheaper price.

Atavistik Bio is using the cash to develop “allosteric” medicines it believes can precisely impact on diseases like ...

The AI drug discovery specialist is the fifth biotechnology company to go public in February and priced the sector’s largest ...

A month after Amgen gave up on rocatinlimab — which was once seen as a threat to Dupixent — new findings have linked the drug ...

Liver-related side effects have led some analysts to question fenebrutinib’s prospects, even though the drug has now cleared ...